These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 21881920)

  • 1. High and continuous exposure of laninamivir, an anti-influenza drug, may work suppressively to generate low-susceptibility mutants in animals.
    Kubo S; Tokumitsu A; Tomozawa T; Kakuta M; Yamashita M
    J Infect Chemother; 2012 Feb; 18(1):69-74. PubMed ID: 21881920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza.
    Yamashita M
    Antivir Chem Chemother; 2010; 21(2):71-84. PubMed ID: 21107016
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Lloren KKS; Kwon JJ; Choi WS; Jeong JH; Ahn SJ; Choi YK; Baek YH; Song MS
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30602610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
    Ikematsu H; Kawai N
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuraminidase mutations conferring resistance to laninamivir lead to faster drug binding and dissociation.
    McKimm-Breschkin JL; Barrett S
    Antiviral Res; 2015 Feb; 114():62-6. PubMed ID: 25499124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [In vitro and in vivo effects of a long-acting anti-influenza agent CS-8958 (laninamivir octanoate, Inavir) against pandemic (H1N1) 2009 influenza viruses].
    Kubo S; Kakuta M; Yamashita M
    Jpn J Antibiot; 2010 Oct; 63(5):337-46. PubMed ID: 21268406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition.
    Vavricka CJ; Li Q; Wu Y; Qi J; Wang M; Liu Y; Gao F; Liu J; Feng E; He J; Wang J; Liu H; Jiang H; Gao GF
    PLoS Pathog; 2011 Oct; 7(10):e1002249. PubMed ID: 22028647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of a single intravenous administration of laninamivir (an active metabolite of laninamivir octanoate) in an influenza virus infection mouse model.
    Kakuta M; Kubo S; Tanaka M; Tobiume S; Tomozawa T; Yamashita M
    Antiviral Res; 2013 Oct; 100(1):190-5. PubMed ID: 23954190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of laninamivir octanoate in mice with advanced inflammation stage caused by infection of highly lethal influenza virus.
    Tomozawa T; Hoshino K; Yamashita M; Kubo S
    J Infect Chemother; 2019 Aug; 25(8):584-588. PubMed ID: 30935767
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Jeong JH; Choi WS; Antigua KJC; Choi YK; Govorkova EA; Webby RJ; Baek YH; Song MS
    J Virol; 2020 Dec; 95(1):. PubMed ID: 33055248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
    Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H
    Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection.
    Sugaya N; Ohashi Y
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2575-82. PubMed ID: 20368393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
    Kubo S; Tomozawa T; Kakuta M; Tokumitsu A; Yamashita M
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1256-64. PubMed ID: 20047917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laninamivir octanoate and artificial surfactant combination therapy significantly increases survival of mice infected with lethal influenza H1N1 Virus.
    Fukushi M; Yamashita M; Miyoshi-Akiyama T; Kubo S; Yamamoto K; Kudo K
    PLoS One; 2012; 7(8):e42419. PubMed ID: 22879974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
    Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI
    Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses.
    Kiso M; Kubo S; Ozawa M; Le QM; Nidom CA; Yamashita M; Kawaoka Y
    PLoS Pathog; 2010 Feb; 6(2):e1000786. PubMed ID: 20195462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus in the Japanese 2012-2013 season.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2015 Jan; 21(1):39-42. PubMed ID: 25277670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
    Koyama K; Nakai D; Takahashi M; Nakai N; Kobayashi N; Imai T; Izumi T
    Drug Metab Dispos; 2013 Jan; 41(1):180-7. PubMed ID: 23091189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A zanamivir dimer with prophylactic and enhanced therapeutic activity against influenza viruses.
    Tarbet EB; Hamilton S; Vollmer AH; Luttick A; Ng WC; Pryor M; Hurst BL; Crawford S; Smee DF; Tucker SP
    J Antimicrob Chemother; 2014 Aug; 69(8):2164-74. PubMed ID: 24777908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A meta-analysis of laninamivir octanoate for treatment and prophylaxis of influenza.
    Higashiguchi M; Matsumoto T; Fujii T
    Antivir Ther; 2018; 23(2):157-165. PubMed ID: 28869418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.